T. Rowe Price Associates
CRNX icon

T. Rowe Price Associates’s Crinetics Pharmaceuticals CRNX Stock Holding History

T. Rowe Price Associates’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$195M Buy
5,355,496
+131,109
+3% +$5.86M 0.02% 467
2025
Q4 		$243M Sell
5,224,387
-81,861
-2% -$3.64M 0.03% 409
2025
Q3 		$221M Sell
5,306,248
-284,256
-5% -$9.09M 0.02% 435
2025
Q2 		$161M Buy
5,590,504
+478,144
+9% +$14.8M 0.02% 480
2025
Q1 		$171M Sell
5,112,360
-302,145
-6% -$11.3M 0.02% 455
2024
Q4 		$277M Buy
5,414,505
+469,748
+9% +$26.3M 0.03% 366
2024
Q3 		$253M Buy
4,944,757
+538,301
+12% +$27.8M 0.03% 391
2024
Q2 		$197M Buy
4,406,456
+583,238
+15% +$26.9M 0.02% 419
2024
Q1 		$179M Buy
3,823,218
+814,360
+27% +$31.9M 0.02% 442
2023
Q4 		$107M Buy
3,008,858
+430,659
+17% +$13.2M 0.01% 529
2023
Q3 		$76.7M Buy
2,578,199
+1,149,289
+80% +$23.7M 0.01% 565
2023
Q2 		$25.8M Buy
1,428,910
+1,387,127
+3,320% +$27.7M ﹤0.01% 871
2023
Q1 		$672K Sell
41,783
-10,148
-20% -$188K ﹤0.01% 1980
2022
Q4 		$951K Sell
51,931
-9,704
-16% -$171K ﹤0.01% 1797
2022
Q3 		$1.21M Buy
61,635
+7,228
+13% +$147K ﹤0.01% 1659
2022
Q2 		$1.01M Buy
54,407
+16,824
+45% +$336K ﹤0.01% 1891
2022
Q1 		$825K Sell
37,583
-39,239
-51% -$794K ﹤0.01% 2096
2021
Q4 		$2.18M Buy
76,822
+10,659
+16% +$263K ﹤0.01% 1680
2021
Q3 		$1.39M Buy
66,163
+238
+0.4% +$4.98K ﹤0.01% 1879
2021
Q2 		$1.24M Buy
65,925
+17,060
+35% +$300K ﹤0.01% 1974
2021
Q1 		$747K Sell
48,865
-32,037
-40% -$497K ﹤0.01% 2187
2020
Q4 		$1.14M Sell
80,902
-5,166
-6% -$72K ﹤0.01% 1879
2020
Q3 		$1.35M Hold
86,068
– – ﹤0.01% 1679
2020
Q2 		$1.51M Buy
86,068
+57,660
+203% +$983K ﹤0.01% 1627
2020
Q1 		$418K Sell
28,408
-7,700
-21% -$158K ﹤0.01% 2060
2019
Q4 		$906K Sell
36,108
-16,175
-31% -$308K ﹤0.01% 1927
2019
Q3 		$786K Sell
52,283
-435,633
-89% -$8.47M ﹤0.01% 1916
2019
Q2 		$12.2M Buy
487,916
+1,786
+0.4% +$44.2K ﹤0.01% 1284
2019
Q1 		$11.1M Buy
486,130
+52,134
+12% +$1.28M ﹤0.01% 1304
2018
Q4 		$13M Buy
433,996
+91
+0% +$2.56K ﹤0.01% 1262
2018
Q3 		$12.4M Buy
+433,905
New +$12.9M ﹤0.01% 1337

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates's CRNX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Crinetics Pharmaceuticals (CRNX) stake by 2.5% in Q1 2026, buying an estimated $5.86M and bringing the position to 5,355,496 shares worth $195M. The position accounts for 0.02% of the portfolio, ranked #467.

T. Rowe Price Associates first reported a position in CRNX in Q3 2018 and has held it in 31 quarters since. The position peaked at $277M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • T. Rowe Price Associates held 5,355,496 shares of Crinetics Pharmaceuticals worth $195M as of Q1 2026.
  • T. Rowe Price Associates bought 131,109 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $5.86M.
  • Crinetics Pharmaceuticals made up 0.02% of T. Rowe Price Associates's portfolio in Q1 2026, its #467 holding.
  • T. Rowe Price Associates first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • T. Rowe Price Associates's Crinetics Pharmaceuticals position peaked at $277M in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.